The evidence on peptides — delivered weekly. Subscribe free →

BPC-157

low risk

Also: Body Protection Compound 157 · Pentadecapeptide BPC-157 · PL-10

Moderate Evidence Research Only

BPC-157 is a pentadecapeptide derived from a gastric juice protective protein. Over 100 animal studies demonstrate broad tissue-protective and healing effects. No completed human RCTs, but Phase II IBD trials have been conducted. One of the most-studied research peptides.

Molecular Weight
1419.5 Da
Formula
C62H98N16O22
Common Dosing
200–500 mcg/day SC or IM, typically in 4–8 week cycles
Category
therapeutic
Last Reviewed
2025-01-15

Reported Benefits

Gut healing / IBD

Moderate Evidence 28 studies

Multiple rodent studies show accelerated gastric ulcer, fistula, and IBD healing.

Tendon repair

Moderate Evidence 19 studies

Promotes collagen synthesis and accelerates tendon-to-bone healing in animal models.

Neuroprotection

Preliminary 11 studies

Reduces dopaminergic system damage in rodent models; some TBI recovery evidence.

Wound healing

Moderate Evidence 22 studies

Accelerates full-thickness wound closure in multiple animal models.

Mechanism of Action

Upregulates GH receptor expression, stimulates angiogenesis via VEGF, activates FAK-paxillin pathway for tendon repair, modulates nitric oxide synthesis.

Key Clinical Studies

Sikiric et al. (2016)

RCT · Animal (rat)

PubMed →

Accelerated GI fistula and IBD healing vs. controls

Overview

BPC-157 remains one of the most researched non-approved peptides. The preclinical data is consistent and mechanistically coherent, but human RCT data is absent. A Phase II IBD trial was conducted by the Croatian group but results were never published in peer-reviewed form.

Regulatory Note

BPC-157 was removed from consideration for the 503A bulk substances list and is not legally available through US compounding pharmacies for human use. The FDA has issued warning letters to vendors.

Most Common Use Cases

GI healing (oral route preferred), tendon/ligament recovery (localized injection), and systemic tissue repair (SC). All use is off-label and experimental.

Regulatory Status

Research Only

Safety Profile

Side Effects

  • •Nausea (oral)
  • •Injection site irritation
  • •Dizziness (rare)

Contraindications

  • •Active malignancy (theoretical)
  • •Pregnancy

Drug Interactions

  • •NSAIDs (may reduce efficacy)

Primary Uses

Gut healingTendon repairNeuroprotectionAnti-inflammatory

Related Peptides

tb-500ll-37ghrp-6

Weekly Briefing

Regulatory updates + new study breakdowns.

For Practitioners

Do you prescribe BPC-157?

Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.

Get Listed →
Disclaimer: This information is for educational and research purposes only. Not medical advice. Consult a qualified healthcare provider before using any compound.